Letters Section Editor: Robert M. Golub, MD, Senior Editor.
In Reply: Dr Ruck and colleagues propose the use of PCCs and their national database, TESS, as a tool for postmarketing drug surveillance. I have long thought that PCCs are an underused resource for the study of dose-related adverse drug reactions.1 After all, what better way to study such reactions than in an overdose setting? However, it is important to place this in proper perspective.
Strom BL. Drug Safety Monitoring—Reply. JAMA. 2006;296(13):1590. doi:10.1001/jama.296.13.1590-b